Search research articles
Contact Us
Filters
Showing results (251-260 of 257) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 257 results.
Nature Chemical Biology
|
May 13, 2020
Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice
Elliot D Mock, Mohammed Mustafa, Ozge Gunduz-Cinar, et al.
Schizophrenia Bulletin Open
|
August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Jean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open
|
August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Jean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia Bulletin
|
May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia
Henry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)
|
March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Kelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)
|
June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Daniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Schizophrenia Bulletin
|
March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Cassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 257) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 257 results.
Nature Chemical Biology
|
May 13, 2020
Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice
Elliot D Mock, Mohammed Mustafa, Ozge Gunduz-Cinar, et al.
Schizophrenia Bulletin Open
|
August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Jean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open
|
August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Jean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia Bulletin
|
May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia
Henry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)
|
March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Kelly Allott, Walid Yassin, Luis Alameda, et al.
Schizophrenia (Heidelberg, Germany)
|
June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Daniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Schizophrenia Bulletin
|
March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Cassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Page
of 26